Literature DB >> 33785843

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Guangna Liu1, Wei Rui1,2, Xueqiang Zhao1,2, Xin Lin3.   

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has achieved successful outcomes against hematological malignancies and provided a new impetus for treating solid tumors. However, the efficacy of CAR-T cells for solid tumors remains unsatisfactory. The tumor microenvironment has an important role in interfering with and inhibiting the effector function of immune cells, among which upregulated inhibitory checkpoint receptors, soluble suppressive cytokines, altered chemokine expression profiles, aberrant vasculature, complicated stromal composition, hypoxia and abnormal tumor metabolism are major immunosuppressive mechanisms. In this review, we summarize the inhibitory factors that affect the function of CAR-T cells in tumor microenvironment and discuss approaches to improve CAR-T cell efficacy for solid tumor treatment by targeting those barriers.

Entities:  

Keywords:  CAR-T; Microenvironment; Tumor

Mesh:

Substances:

Year:  2021        PMID: 33785843      PMCID: PMC8093220          DOI: 10.1038/s41423-021-00655-2

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  172 in total

1.  Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.

Authors:  Edmund K Moon; Carmine Carpenito; Jing Sun; Liang-Chuan S Wang; Veena Kapoor; Jarrod Predina; Daniel J Powell; James L Riley; Carl H June; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

2.  Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

Authors:  Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2017-10-04       Impact factor: 66.675

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Authors:  Gregory L Beatty; Mark H O'Hara; Simon F Lacey; Drew A Torigian; Farzana Nazimuddin; Fang Chen; Irina M Kulikovskaya; Michael C Soulen; Maureen McGarvey; Anne Marie Nelson; Whitney L Gladney; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June
Journal:  Gastroenterology       Date:  2018-03-20       Impact factor: 22.682

6.  Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Authors:  Nabil Ahmed; Vita S Brawley; Meenakshi Hegde; Catherine Robertson; Alexia Ghazi; Claudia Gerken; Enli Liu; Olga Dakhova; Aidin Ashoori; Amanda Corder; Tara Gray; Meng-Fen Wu; Hao Liu; John Hicks; Nino Rainusso; Gianpietro Dotti; Zhuyong Mei; Bambi Grilley; Adrian Gee; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Winfried S Wels; Lisa L Wang; Peter Anderson; Stephen Gottschalk
Journal:  J Clin Oncol       Date:  2015-03-23       Impact factor: 44.544

7.  Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors:  Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151

8.  Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Authors:  Jae H Park; Isabelle Rivière; Mithat Gonen; Xiuyan Wang; Brigitte Sénéchal; Kevin J Curran; Craig Sauter; Yongzeng Wang; Bianca Santomasso; Elena Mead; Mikhail Roshal; Peter Maslak; Marco Davila; Renier J Brentjens; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

9.  Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.

Authors:  Donghua Shi; Yaoping Shi; Ahmed O Kaseb; Xingxing Qi; Yuan Zhang; Jiachang Chi; Qing Lu; Huiping Gao; Hua Jiang; Huamao Wang; Daijing Yuan; Hong Ma; Hongyang Wang; Zonghai Li; Bo Zhai
Journal:  Clin Cancer Res       Date:  2020-05-05       Impact factor: 12.531

10.  HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Authors:  Nabil Ahmed; Vita Brawley; Meenakshi Hegde; Kevin Bielamowicz; Mamta Kalra; Daniel Landi; Catherine Robertson; Tara L Gray; Oumar Diouf; Amanda Wakefield; Alexia Ghazi; Claudia Gerken; Zhongzhen Yi; Aidin Ashoori; Meng-Fen Wu; Hao Liu; Cliona Rooney; Gianpietro Dotti; Adrian Gee; Jack Su; Yvonne Kew; David Baskin; Yi Jonathan Zhang; Pamela New; Bambi Grilley; Milica Stojakovic; John Hicks; Suzanne Z Powell; Malcolm K Brenner; Helen E Heslop; Robert Grossman; Winfried S Wels; Stephen Gottschalk
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

View more
  14 in total

Review 1.  Extracellular vesicle-mediated immunoregulation in cancer.

Authors:  Tomofumi Yamamoto; Yusuke Yamamoto; Takahiro Ochiya
Journal:  Int J Hematol       Date:  2022-08-11       Impact factor: 2.319

Review 2.  Systematic Investigation of Biocompatible Cationic Polymeric Nucleic Acid Carriers for Immunotherapy of Hepatocellular Carcinoma.

Authors:  Mingsheng Chen; Hao Wang; Hongying Guo; Ying Zhang; Liang Chen
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

Review 3.  Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.

Authors:  David C Soler; Amber Kerstetter-Fogle; Thomas S McCormick; Andrew E Sloan
Journal:  J Neurooncol       Date:  2021-11-26       Impact factor: 4.130

Review 4.  Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.

Authors:  Hyunmin Chung; Haiyoung Jung; Ji-Yoon Noh
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

Review 5.  Implementing Logic Gates for Safer Immunotherapy of Cancer.

Authors:  Mohammed Azharuddin Savanur; Hadas Weinstein-Marom; Gideon Gross
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

Review 6.  Immunological configuration of ovarian carcinoma: features and impact on disease outcome.

Authors:  Jitka Fucikova; An Coosemans; Sandra Orsulic; David Cibula; Ignace Vergote; Lorenzo Galluzzi; Radek Spisek
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

7.  A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

Authors:  Lele Miao; Juan Zhang; Zhengchao Zhang; Song Wang; Futian Tang; Muzhou Teng; Yumin Li
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 8.  The potential of CAR T cell therapy for prostate cancer.

Authors:  Philipp Wolf; Jamal Alzubi; Christian Gratzke; Toni Cathomen
Journal:  Nat Rev Urol       Date:  2021-07-08       Impact factor: 14.432

9.  Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response.

Authors:  Can Liu; Timothy Qi; J Justin Milner; Yong Lu; Yanguang Cao
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 8.786

Review 10.  Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions.

Authors:  John A Ligon; Kristin M Wessel; Nirali N Shah; John Glod
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.